C4 Therapeutics Ownership
| CCCC Stock | USD 4.38 0.13 3.06% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 68.8 M | Current Value 69.6 M | Avarage Shares Outstanding 45.7 M | Quarterly Volatility 14.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
CCCC |
CCCC Stock Ownership Analysis
About 92.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.24. Some equities with similar Price to Book (P/B) outperform the market in the long run. C4 Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.07. The entity recorded a loss per share of 1.71. The firm had not issued any dividends in recent years. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people. For more info on C4 Therapeutics please contact Andrew MBA at 617 231 0700 or go to https://www.c4therapeutics.com.Besides selling stocks to institutional investors, C4 Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different C4 Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align C4 Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
C4 Therapeutics Quarterly Liabilities And Stockholders Equity |
|
C4 Therapeutics Insider Trades History
About 11.0% of C4 Therapeutics are currently held by insiders. Unlike C4 Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against C4 Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of C4 Therapeutics' insider trades
CCCC Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as C4 Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading C4 Therapeutics backward and forwards among themselves. C4 Therapeutics' institutional investor refers to the entity that pools money to purchase C4 Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Advisers, Llc | 2024-06-30 | 1.4 M | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 1.3 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.2 M | Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 1.1 M | Two Sigma Investments Llc | 2024-09-30 | 828.5 K | Goldman Sachs Group Inc | 2024-06-30 | 737.8 K | Tang Capital Management Llc | 2024-09-30 | 700 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 578.9 K | Wasatch Advisors Lp | 2024-09-30 | 5.7 M | Ra Capital Management, Llc | 2024-09-30 | 4.9 M |
C4 Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific C4 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on C4 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases C4 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
C4 Therapeutics Outstanding Bonds
C4 Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. C4 Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CCCC bonds can be classified according to their maturity, which is the date when C4 Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| CF Industries 515 Corp BondUS12527GAF00 | View | |
| CF Industries 495 Corp BondUS12527GAD51 | View | |
| CF INDS INC Corp BondUS12527GAE35 | View | |
| US12527GAH65 Corp BondUS12527GAH65 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
C4 Therapeutics Corporate Filings
F3 | 21st of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.522 | Quarterly Revenue Growth 0.387 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.